Plain-English translation of NCT06902272 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether a blood test that detects circulating tumor DNA—tiny pieces of cancer DNA floating in your blood—can help doctors predict how well you'll respond to chemotherapy and immunotherapy for early-stage lung cancer. The study will also investigate whether , an immunotherapy drug, can help prevent cancer from returning in patients who have detectable tumor DNA or evidence of remaining cancer after surgery.
Current methods of checking whether cancer treatment is working or whether any cancer remains after surgery have limitations. This medication has shown promise in lung cancer, but doctors need better tools to predict who will benefit most and to catch any returning cancer as early as possible.
You likely qualify if…
You likely don't qualify if…
You would receive standard chemotherapy and immunotherapy before surgery, followed by surgical removal of your tumor, with regular blood tests throughout to monitor your tumor DNA levels. Your participation would last up to 2.5 years, during which you'll have multiple clinic visits for treatment, surgery, blood draws, and follow-up appointments to see how well the treatment worked and whether any cancer returns.
AI-generated summary from trial data · Jun 9, 2026 · Not medical advice
United States